Pressmeddelande -
Sanofi to present new clinical data, including results from the investigational new insulin U300, at the American Diabetes Association 73rd Scientific Sessions
Paris, France - June 18, 2013 – Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that clinical data highlighting the company’s ongoing commitment to advancing diabetes care will be presented at the American Diabetes Association (ADA) 73rd Scientific Sessions in Chicago, USA (June 21−25, 2013). In total, more than 60 abstracts representing new data sets on Sanofi diabetes drugs, investigational drugs or medical devices are part of the official scientific program.
“The American Diabetes Association annual meeting provides an important opportunity for Sanofi to share significant data with the medical community and to demonstrate our focus on advancing scientific thinking in the field of diabetes treatment,” said Pierre Chancel, Senior Vice President, Global Diabetes at Sanofi. “The data being presented further support the company’s leadership in integrated diabetes care and delivering personalized solutions that directly target the needs of people living with this disease.”
Among the study findings being presented in poster and oral scientific sessions are the following (abstracts have been posted on the ADA website):
Investigational new insulin U300
The EDITION I study compared
the efficacy and safety of investigational new insulin U300 vs. Lantus®
(insulin glargine) in people with type 2 diabetes using basal plus mealtime
insulin. The EDITION I study is part of a larger Phase III clinical program.
"New insulin glargine formulation: glucose control and
hypoglycemia in people with type 2 diabetes using basal and mealtime insulin
(EDITION I)"
Embargo lifts: Saturday, June 22, 10 am CST
Presenter: M. Riddle, Oregon Health and Science University, Portland,
USA
Location: Poster Hall
The pharmacodynamic and pharmacokinetic properties of the investigational new insulin U300 were examined in a double-blind, randomized study in patients with type 1 diabetes:
"Euglycemic clamp profile of new insulin glargine U300
formulation in patients with type 1 diabetes (T1DM) is different from glargine
U100"
Embargo lifts: Saturday, June 22, 10 am CST
Presenter: R. Dahmen, Sanofi, Frankfurt am Main, Germany
Location: Poster Hall (also available as an ePoster
on the ADA website after 10 am, June 22)
"New insulin glargine U300 formulation evens and prolongs steady
state PK and PD profiles during euglycemic clamp in patients with type 1
diabetes (T1DM)"
Embargo lifts: Saturday, June 22, 1:45 pm CST
Presenter: T. Jax, Profil, Neuss, Germany
Location: W-375A
Lyxumia® (lixisenatide)*
Lyxumia®, the first
once-daily prandial GLP-1 receptor agonist, is approved in the European Union for
the treatment of adults with type 2 diabetes mellitus to achieve glycemic
control in combination with oral glucose-lowering medicinal products and/or
basal insulin when these, together with diet and exercise, do not provide
adequate glycemic control.
Lyxumia® data include two analyses investigating its post-prandial mechanism of action:
"Once-daily lixisenatide as add-on to basal insulin ± OADs in
patients with type 2 diabetes selectively reduces postprandial hyperglycemic
daytime exposure"
Embargo lifts: Saturday, June 22, 10 am
CST
Presenter: M. Riddle, Oregon Health and Science University, Portland,
USA
Location: Poster Hall (also available as an ePoster
on the ADA website after 10 am, June 22)
"Efficacy of lixisenatide in the GetGoal clinical trial program:
pooled analysis of postprandial metabolic outcomes"
B. Ahrén, Lund University,
Sweden. Abstract publication only.
Further data include analyses of the effects of Lyxumia® in combination with basal insulin on HbA1c, weight gain and symptomatic hypoglycemia in patients with type 2 diabetes:
"Expanding the basal-plus regimen: basal insulin + lixisenatide
is more likely to achieve the composite outcome of HbA1c <7%, no
documented symptomatic hypoglycemia and no weight gain compared with basal +
prandial insulin"
Embargo lifts: Saturday, June 22, 10 am
CST
Presenter: J. Rosenstock, Dallas Diabetes & Endocrine Center,
Texas, USA
Location: Poster Hall (also available as an ePoster
on the ADA website after 10 am, June 22)
"Meta-analysis of randomized controlled trials of lixisenatide as
add-on to basal insulin in patients with type 2 diabetes mellitus"
Embargo lifts: Saturday, June 22, 10 am
CST
Presenter: B. Charbonnel, University of Nantes, France
Location: Poster Hall (also available as an ePoster
on the ADA website after 10 am, June 22)
ORIGIN (Outcome Reduction with Initial Glargine INtervention) [1]
ORIGIN is a unique, seven-year
landmark cardiovascular (CV) outcomes trial, evaluating Lantus® vs.
standard care in over 12,500 individuals who are at high CV risk with
pre-diabetes or early type 2 diabetes mellitus. Spanning 40 countries
worldwide, it is the world’s longest and largest randomized clinical trial of
its type in this population, and the first to formally evaluate the effects of
insulin on CV outcomes.
Results from a new sub-analysis of ORIGIN will be presented:
"Cancer outcomes in patients with dysglycemia on basal insulin: results
of the ORIGIN trial”
Embargo lifts: Monday, June 24, 8 am CST
Presenter: LJ. Bordeleau, McMaster University, Ontario,
Canada
Location: S-103B
ATLAS (Asian Treat to Target Lantus® Study)
The ATLAS study compared the
effectiveness of a patient-led vs. physician-led initiation of Lantus®
in 552 patients with type 2 diabetes in Asia and Russia. Due to the specific
challenges faced by people living with diabetes in Asia, this study
investigated whether self-adjustment of insulin in this population is similarly
effective at lowering blood glucose levels as it is in Western diabetes
patients.
Data from ATLAS includes:
"Asian Treat to Target Lantus Study (ATLAS): a 24 week
randomized, multinational study"
Embargo lifts: Saturday, June 22, 10 am
CST
Presenter: S. Garg, University of Colorado Health
Sciences Center, Denver, Colorado, USA
Location: Poster Hall
"Evaluating the patient experience in the Asian Treat to Target
Lantus Study (ATLAS): a 24-week randomized, multinational study"
Embargo lifts: Saturday, June 22, 10 am
CST
Presenter: N. Freemantle, University College London,
UK
Location: Poster Hall
BGStar®
Now available in 14 countries
across four continents, our intuitive blood glucose monitoring (BGM) devices BGStar®
and iBGStar® form a key part of our comprehensive patient-centric
portfolio and are at the heart of our integrated approach to diabetes.
Key BGStar® data show that the performance of our self-monitoring BGM device achieves similar system accuracy as point of care testing systems for professional use:
"Evaluating system accuracy of blood glucose monitoring systems
for point of care testing"
Embargo lifts: Saturday, June 22, 10 am
CST
Presenter: G.
Freckmann, Institut für Diabetes-Technologie Forschungs- und
Entwicklungsgesellschaft mbH an der Universität Ulm, Germany
Location: Poster Hall (also available as an ePoster
on the ADA website after 10 am, June 22)
Sanofi will host a conference call for the financial community during the upcoming ADA 73rd Scientific Sessions. The call will include results from the ongoing EDITION Phase III program for the company's investigational new insulin U300 as well as a status update on the fixed-ratio combination of insulin glargine and lixisenatide.
The conference call will take place on Monday June 24, 2013, at 7 am CST (2 pm CET). Dial-in numbers and the audio webcast link will be accessible via www.sanofi.com
About Diabetes
Diabetes
is a chronic disease that occurs as type 1 diabetes, which is an autoimmune
disease characterized by the lack of insulin (the hormone that regulates blood
glucose concentrations) production by the pancreas, and type 2, a metabolic
disorder in which there are two main biological defects: a deficient production
of insulin and reduced ability of the body to respond to the insulin being
produced. Type 1 and type 2 diabetes are characterized by an increase in blood
glucose concentrations (hyperglycemia). Over time, uncontrolled hyperglycemia
leads to the macrovascular and microvascular complications of diabetes.
Macrovascular complications, which affect the large blood vessels, include
heart attack, stroke and peripheral vascular disease. Microvascular
complications affect the small blood vessels of the eyes (retinopathy), kidney
(nephropathy) and nerves (neuropathy). The global incidence of diabetes is
growing at an alarming rate, with more than 371 million people worldwide living
with the condition today.[2]
About Sanofi Diabetes
Sanofi strives to help people manage the
complex challenge of diabetes by delivering innovative, integrated and
personalized solutions. Driven by valuable insights that come from listening to
and engaging with people living with diabetes, the Company is forming
partnerships to offer diagnostics, therapies, services and devices, including
blood glucose monitoring systems. Sanofi markets both injectable and oral
medications for people with type 1 or type 2 diabetes.
About Sanofi
Sanofi, an integrated global healthcare
leader, discovers, develops and distributes therapeutic solutions focused on
patients’ needs. Sanofi has core strengths in the field of healthcare with
seven growth platforms: diabetes solutions, human vaccines, innovative drugs,
consumer healthcare, emerging markets, animal health and the new Genzyme.
Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Footnote
*Lixisenatide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), was
in-licensed from Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL), www.zealandpharma.com, and is approved in Europe, Mexico and Australia for the treatment of patients
with type 2 diabetes mellitus. Lyxumia is the proprietary name approved by the
EMA, Australia and Mexico, and submitted to other health authorities for the
GLP-1 RA lixisenatide. The proprietary name for lixisenatide in the United
States is under consideration.
References
1.
Gerstein
H (ORIGIN Trail Investigators) et al. Basal Insulin and Cardiovascular and
Other Outcomes in Dysglycemia. New England Journal of Medicine 2012; 367: 319‒328.
2.
International Diabetes Federation. IDF
Diabetes Atlas, 5th edition: 2012 update. Brussels, Belgium, 2011.
http://www.idf.org/diabetesatlas (Accessed: June, 2013)
Forward-Looking Statements
This
press release contains forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect to future
financial results, events, operations, services, product development and
potential, and statements regarding future performance. Forward-looking
statements are generally identified by the words “expects”, “anticipates”,
“believes”, “intends”, “estimates”, “plans” and similar expressions. Although
Sanofi’s management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and uncertainties, many
of which are difficult to predict and generally beyond the control of Sanofi,
that could cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking information
and statements. These risks and uncertainties include among other things, the
uncertainties inherent in research and development, future clinical data and
analysis, including post marketing, decisions by regulatory authorities, such
as the FDA or the EMA, regarding whether and when to approve any drug, device
or biological application that may be filed for any such product candidates as
well as their decisions regarding labelling and other matters that could affect
the availability or commercial potential of such product candidates, the
absence of guarantee that the product candidates if approved will be
commercially successful, the future approval and commercial success of
therapeutic alternatives, the Group’s ability to benefit from external growth
opportunities, trends in exchange rates and prevailing interest rates, the
impact of cost containment policies and subsequent changes thereto, the average
number of shares outstanding as well as those discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including those listed
under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking
Statements” in Sanofi’s annual report on Form 20-F for the year ended December
31, 2012. Other than as required by applicable law, Sanofi does not undertake
any obligation to update or revise any forward-looking information or
statements.
Contacts:
Corporate Media Relations
Marisol Péron
Tel: + (33) 1 53 77 45 02
Mobile: + (33) 6 08 18 94 78
E-mail: marisol.peron@sanofi.com
Investor Relations
Sébastien Martel
Tel: + (33) 1 53 77 45 45
E-mail: ir@sanofi.com
Global Diabetes Division
Communications
Phil McNamara
Tel: + (1) 908 981 5497
Mobile: + (1) 908 210 4047
E-mail: philip.mcnamara@sanofi.com
Ämnen
Kategorier
Sanofi är ett ledande globalt läkemedelsföretag som identifierar, utvecklar och distribuerar behandlingslösningar som syftar till att förbättra människors liv. Sanofi inriktar sig på sju stora områden: diabetesbehandling, vacciner, innovativa läkemedel, sällsynta sjukdomar, egenvårdsprodukter, utvecklingsmarknader och veterinärmedicin. Sanofi är börsnoterat i Paris (EURONEXT: SAN) och i New York (NYSE: SNY). www.sanofi.se